173 related articles for article (PubMed ID: 11160862)
1. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.
Siegel D; Anwar A; Winski SL; Kepa JK; Zolman KL; Ross D
Mol Pharmacol; 2001 Feb; 59(2):263-8. PubMed ID: 11160862
[TBL] [Abstract][Full Text] [Related]
2. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1.
Anwar A; Siegel D; Kepa JK; Ross D
J Biol Chem; 2002 Apr; 277(16):14060-7. PubMed ID: 11821413
[TBL] [Abstract][Full Text] [Related]
4. Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap 'n' collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduction.
Ma Q; Kinneer K; Bi Y; Chan JY; Kan YW
Biochem J; 2004 Jan; 377(Pt 1):205-13. PubMed ID: 14510636
[TBL] [Abstract][Full Text] [Related]
5. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
[TBL] [Abstract][Full Text] [Related]
6. Cytosolic components are required for proteasomal degradation of newly synthesized apolipoprotein B in permeabilized HepG2 cells.
Sakata N; Stoops JD; Dixon JL
J Biol Chem; 1999 Jun; 274(24):17068-74. PubMed ID: 10358059
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).
Traver RD; Siegel D; Beall HD; Phillips RM; Gibson NW; Franklin WA; Ross D
Br J Cancer; 1997; 75(1):69-75. PubMed ID: 9000600
[TBL] [Abstract][Full Text] [Related]
8. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C.
Tai HL; Fessing MY; Bonten EJ; Yanishevsky Y; d'Azzo A; Krynetski EY; Evans WE
Pharmacogenetics; 1999 Oct; 9(5):641-50. PubMed ID: 10591545
[TBL] [Abstract][Full Text] [Related]
9. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53.
Gong X; Kole L; Iskander K; Jaiswal AK
Cancer Res; 2007 Jun; 67(11):5380-8. PubMed ID: 17545619
[TBL] [Abstract][Full Text] [Related]
10. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.
Sheaff RJ; Singer JD; Swanger J; Smitherman M; Roberts JM; Clurman BE
Mol Cell; 2000 Feb; 5(2):403-10. PubMed ID: 10882081
[TBL] [Abstract][Full Text] [Related]
11. Role of ubiquitin in proteasomal degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum.
Teckman JH; Gilmore R; Perlmutter DH
Am J Physiol Gastrointest Liver Physiol; 2000 Jan; 278(1):G39-48. PubMed ID: 10644560
[TBL] [Abstract][Full Text] [Related]
12. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.
Aviel S; Winberg G; Massucci M; Ciechanover A
J Biol Chem; 2000 Aug; 275(31):23491-9. PubMed ID: 10807912
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes.
Boudjelal M; Wang Z; Voorhees JJ; Fisher GJ
Cancer Res; 2000 Apr; 60(8):2247-52. PubMed ID: 10786691
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
15. 'ER degradation' of a mutant yeast plasma membrane protein by the ubiquitin-proteasome pathway.
Galan JM; Cantegrit B; Garnier C; Namy O; Haguenauer-Tsapis R
FASEB J; 1998 Mar; 12(3):315-23. PubMed ID: 9506475
[TBL] [Abstract][Full Text] [Related]
16. Proteasome-dependent degradation of the human estrogen receptor.
Nawaz Z; Lonard DM; Dennis AP; Smith CL; O'Malley BW
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):1858-62. PubMed ID: 10051559
[TBL] [Abstract][Full Text] [Related]
17. Polyamine analogues inhibit the ubiquitination of spermidine/spermine N1-acetyltransferase and prevent its targeting to the proteasome for degradation.
Coleman CS; Pegg AE
Biochem J; 2001 Aug; 358(Pt 1):137-45. PubMed ID: 11485561
[TBL] [Abstract][Full Text] [Related]
18. Accelerated ubiquitination and proteasome degradation of a genetic variant of inducible nitric oxide synthase.
Ying WZ; Sanders PW
Biochem J; 2003 Dec; 376(Pt 3):789-94. PubMed ID: 12959638
[TBL] [Abstract][Full Text] [Related]
19. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
[TBL] [Abstract][Full Text] [Related]
20. An ATP-stabilized inhibitor of the proteasome is a component of the 1500-kDa ubiquitin conjugate-degrading complex.
Driscoll J; Frydman J; Goldberg AL
Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4986-90. PubMed ID: 1317579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
